Recent studies found that MALT1 is required to activate the NF-κB signaling and promote cancer progression in the non-lymphoid system, such as breast cancer, lung cancer, melanoma, and cholangiocarcinoma [24,25,26,27]. This evidence concerns the gene NFKB1 and breast carcinoma.